Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RD

Key facts

Sponsor

Wen Zhang

Principal Investigator

Wen Zhang, MD

Peking Union Medical College Hospital

Intervention

Prednisolone(drug)

Enrollment

74 enrolled

Eligibility

18-70 years · All sexes

Timeline

2023 – 2025

Study locations (1)

• Peking Union Medical College Hospital, Beijing, Bejing, China

Collaborators

Tongji Hospital · Beijing Friendship Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for IgG4-related disease

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT07061938
  Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
  Acepodia Biotech, Inc.
• RECRUITINGPHASE2NCT07025330
  A Study of Efgartigimod in Patients With IgG4-Related Disease
  Stanford University
• RECRUITINGPHASE3NCT07190196
  A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
  Sanofi
• RECRUITINGPHASE2NCT07148791
  Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease
  Chinese PLA General Hospital
• RECRUITINGPHASE2, PHASE3NCT07068165
  A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease
  Peking Union Medical College Hospital
• RECRUITINGNANCT07104058
  A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD
  Luo Yaping
• ACTIVE NOT RECRUITINGNCT06844864
  Adaptive and Trained Immunity in the Pathogenesis of IgG4-Related Disease
  IRCCS San Raffaele
• RECRUITINGEARLY PHASE1NCT06497387
  Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
  Tongji Hospital

See all trials for IgG4-related disease →